Scientists at UCSF and the Parker Institute of Cancer Immunotherapy have developed methods for characterizing dendritic cells as well as methods for identifying a dendritic cell as either an inflammatory or a tolerogenic dendritic cell. Their results provide important insights into previously obscured metabolic heterogeneity impacting immune profiles of immunogenic and tolerogenic dendritic cells (DC).
There have been over 200 clinical trials testing dendritic cell-based vaccines; however, there have not been much commercial successes to date. The proposed invention offers researchers approaches to identify potential biomarkers and key pathways for monocyte-derived dendritic cell-based vaccines against cancer or vaccines to inhibit autoimmunity. Researchers can use their signaling pathway findings ratio to direct drug treatments that will reprogram DC in 1) cancer towards more effective inflammatory DC activity, and 2) in autoimmunity to suppress unwanted immunity by using drugs to skew DC to tolerance.
This novel invention provides the following advantages: